Skip to main content
SpringerLink
Log in

IL-17, IL-10, IL-6, and IFN-γ in Egyptian Behçet’s disease: correlation with clinical manifestations

  • Research Article
  • Published:
European Cytokine Network Aims and scope

Abstract

There are a limited number of studies that report the polarization of the immune system toward the production of T helper 1 (Th1), Th2, or Th17-type cytokines in patients with Behçet’s disease (BD). Here, we aimed to detect the presence of various cytokines in serum samples of Egyptian BD patients and to determine the correlation between their production levels and clinical manifestations. To that aim, serum levels of IFN-γ, IL-10, IL-6, and IL-17 measured by ELISA were determined in BD patients with active or inactive disease to evaluate their clinical relevance. The results of the present study show significantly elevated levels of IL-17 and IL-6, as well as a reduction in IL-10, and no change in IFN-γ, in sera of BD patients, as compared to the healthy control group. Moreover, IL-6 serum levels were increased in BD patients in active stages of disease and correlated with arthritic manifestations. On the other hand, IL-10 serum levels were significantly decreased in patients with gastrointestinal tract complications. Furthermore, a positive correlation was observed between IL-10 serum levels and ocular manifestations in BD patients, in contrast to those of IL-17, showing no correlation with the different clinical manifestations. Taken together, the magnitude of IL-6 serum levels could be a potential marker for arthritic manifestations and disease activity, whereas those of IFN-γ, IL-10, and IL-17 cannot be considered predictors for different clinical manifestations in patients with BD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun Highlights 2016; 7: 4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Puccetti A, Pelosi A, Fiore FP, Patuzzo G, Lunardi C, Dolcino M. MicroRNA expression profiling in Behçet’s disease. J Immunol Res 2018; 2405150.

  3. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun Highlights 2016; 7: 4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gallizzi R, De Vivo D, Valenti S, Pidone C, Romeo C, Caruso R, Claudio Romano R. Intestinal and neurological involvement in Behçet disease: a clinical case. Ital J Pediatr 2017; 43: 33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205.

    Article  PubMed  Google Scholar 

  6. Shimizu J, Yoshikawa H, Takada E, Hirotsu C, Suzuki N. Unbalanced helper T cell function in Behçet’s disease. Inflamm Regen 2011; 31: 297.

    Article  Google Scholar 

  7. Sadeghi A, Davatchi F, Shahram F, Karimimoghadam A, Alikhani M, Pezeshgi A, Mazloomzadeh S, Sadeghi-Abdollahi B, Asadi-Khiavi M. Serum profiles of cytokines in Behçet’s disease. J Clin Med 2017; 6: 49.

    Article  CAS  PubMed Central  Google Scholar 

  8. Takeuchi M, Karasawa Y, Harimoto K, Tanaka A, Shibata M, Sato T, Caspi RR, Ito M. Analysis of Th Cell-related cytokine production in Behçet disease patients with uveitis before and after infliximab treatment. Ocul Immunol Inflamm 2017; 25: 52.

    Article  CAS  PubMed  Google Scholar 

  9. Chi W, Yang P, Zhu X, et al. Production of interleukin-17 in Behçet’s disease is inhibited by cyclosporin A. Mol Vis 2010; 19: 880.

    Google Scholar 

  10. Liang L, Wang H, Peng XY, Zhao M. The changes of Thelper lymphocyte subsets in patients with Behçet’s disease. Zhonghua YanKe ZaZhi 2011; 47: 393.

    Google Scholar 

  11. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet’s disease. Arthritis Res Ther 2012; 14.

  12. Lin CF, Lin CM, Lee KY, Wu SY, Feng PH, Chen KYHC, Chen CL, Wang YC, Tseng PC, Tsai TT. Escape from IFN-γ-dependent immunosurveillance in tumorigenesis. J Biomed Sci 2017; 24: 10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rosloniec EF, Latham K, Guedez YB. Paradoxical role of IFN-γ in models of Th1-mediated autoimmunity. Arthritis Res 2002; 4: 333.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566.

    Article  CAS  PubMed  Google Scholar 

  15. Kubo M, Motomura Y. Transcriptional regulation of the antiinflammatory cytokine IL-10 in acquired immune cells. Front Immunol 2012; 3: 275.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fitzgerald DC, Zhang GX, El-Behi M, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007; 8: 1372.

    Article  CAS  PubMed  Google Scholar 

  17. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180: 5771.

    Article  CAS  PubMed  Google Scholar 

  18. Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nat Immunol 2000; 6: 465.

    Article  CAS  Google Scholar 

  19. Yu CR, Mahdi RM, Ebong S, Vistica BP, Gery I, Egwuagu CE. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem 2003; 278: 29752.

    Article  CAS  PubMed  Google Scholar 

  20. Kim ES, Kim SW, Moon CM, et al. Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behçet’s disease in Korean population. Life Sci 2012; 90: 740.

    Article  CAS  PubMed  Google Scholar 

  21. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235–8.

    Article  CAS  PubMed  Google Scholar 

  22. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet’s disease. Ann Acad Med Singapore 2004; 33: 596–9.

    CAS  PubMed  Google Scholar 

  23. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335(8697):1078.

    Google Scholar 

  24. Aydintug AO, Tokgöz G, Özoran K, Düzgün N, Gürler A, Tutkak H. Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behçet’s disease. Rheumatol Int 1995; 15: 75.

    Article  CAS  PubMed  Google Scholar 

  25. Talaat RM, El-Bassiouny AI, Osman AM, Yossif M, Charmy R, Al-Sherbiny MM. Cytokine secretion profile associated with periportal fibrosis in S. mansoni infected Egyptian patients. Parasitol Res 2007; 101: 289.

    Article  PubMed  Google Scholar 

  26. Talaat RM. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol 2010; 23: 151.

    Article  CAS  PubMed  Google Scholar 

  27. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821.

    Article  CAS  PubMed  Google Scholar 

  28. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behçet’s disease. Autoimmun Rev 2012; 11: 699.

    Article  CAS  PubMed  Google Scholar 

  29. Akkurt ZM, Bozkurt M, Ucmak D, Uksel Y, Ucak H, Sula B, Özkurt GZ, Yildiz M, Akdeniz D, Arica M. Serum cytokine levels in Behçet’s disease. J Clin Lab Anal 2015; 29: 317.

    Article  CAS  PubMed  Google Scholar 

  30. Central Hirohata S. Nervous system involvement in Behçets disease. RinshoShinkeigazu 2001; 41: 1147.

    Google Scholar 

  31. Akman A, Ekinsi NC, Kacaroglu H, et al. Relationship between Turkish patients and Behçet’s disease. Arch Dermatol Res 2008; 300: 19.

    Article  CAS  PubMed  Google Scholar 

  32. Koarada S, Haruta Y, Tada Y, et al. Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behçet’s disease. Rheumatology (Oxford) 2004; 43: 843.

    Article  CAS  Google Scholar 

  33. Nalbant S, Sahan B, Durna M, et al. Cytokine profile in Behçet uveitis. Bratisl Lek Listy 2008; 109: 551.

    CAS  PubMed  Google Scholar 

  34. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. J Scleroderma Relat Disord 2017; 2(Suppl. 2):S1–5.

    Google Scholar 

  35. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002; 1592: 323.

    Article  CAS  PubMed  Google Scholar 

  36. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012; 11: 687.

    Article  CAS  PubMed  Google Scholar 

  37. Fessler JB. Vasculitis and related diseases. In: Koopman WJ, Moreland LW, (eds). Arthritis and allied conditions. Philadelphia, Pa, USA: Lippincott Williams and Wilkins;1835–44.

  38. Frikha F, Marzouk S, Kaddour N, Frigui M, Bahloul Z. Destructive arthritis in Behçet’s disease: a report of eight cases and literature review. Int J Rheum Dis 2009; 12: 250.

    Article  CAS  PubMed  Google Scholar 

  39. Hirano T, Ohguro N, Hohki S, et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298.

    Article  PubMed  Google Scholar 

  40. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum 2004; 50: 2291.

    Article  CAS  PubMed  Google Scholar 

  41. Jiang S, Liu X, Luo L, et al. Serum levels of Th17-related cytokines in Behçet disease patients after cataract surgery. Mol Vis 2011; 17: 1425.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Pollard KM, Cauvi DM, Toomey CB, Morris KV, Kono DH. Interferon-γ and systemic autoimmunity. Discov Med 2013; 16: 123.

    PubMed  PubMed Central  Google Scholar 

  43. Ramya S, Gaddam S. Cytokines that mediate and regulate immune responses; 2015. http://austinpublishinggroup.com/ebooks/innovative-immunology/chapters/II-14-05.pdf (innovative immunology, ISBN: 978-0-9971499-1-3).

  44. Zhang J. Yin and yang interplay of IFN-γ in inflammation and autoimmune disease. J Clin Investig 2007; 117: 871–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Belguendouz H, Messaoudene D, Lahmar K, et al. Interferongamma and nitric oxide production during Behçet uveitis. immunomodulatory effect of IL-10. J Interferon Cytokine Res 2011; 21: 643–51.

    Article  CAS  Google Scholar 

  46. Ilhan F, Demir T, Türkçüoglu P, Turgut B, Demir N, Gödekmerdan A. Th1 polarization of the immune response in uveitis in Behçet’s disease. Can J Ophthalmol 2008; 43: 105.

    Article  PubMed  Google Scholar 

  47. Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behçet disease. Eur J Ophthalmol 2009; 19: 998.

    Article  PubMed  Google Scholar 

  48. Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th17 and RORyt mRNA in Behçet’s disease. Med Sci Monit 2011; 17: 227.

    Article  Google Scholar 

  49. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K. ATP drives lamina propria TH17 cell differentiation. Nature 2008; 455: 808.

    Article  CAS  PubMed  Google Scholar 

  50. Guo B. IL-10 modulates Th17 pathogenicity during autoimmune diseases. J Clin Cell Immunol 2016; 7: 400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S. Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet’s disease. J Dermatol 2003; 30: 602.

    Article  CAS  PubMed  Google Scholar 

  52. Vaccarino L, Triolo G, Palombo AA, Scola L, Palmeri M, Bova M, Candore G, Lio D, Balistreri CR. Pathological implications of Th1/Th2 cytokine genetic variants in Behçet’s disease: data from a pilot study in a Sicilian population. Biochem Genet 2013; 51(11–12):967–75. doi: https://doi.org/10.1007/s10528-013-9621-x.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City, Egypt

    Roba M. Talaat

  2. Medical Physiology Department, National Research Centre (NRC), Dokki, Cairo, Egypt

    Hiba Sibaii & Amany El-Wakkad

  3. Faculty of Medicine, Rheumatology and Rehabilitation Department, Cairo University, Cairo, Egypt

    Iman H. Bassyouni

Authors
  1. Roba M. Talaat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiba Sibaii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iman H. Bassyouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amany El-Wakkad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiba Sibaii.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Talaat, R.M., Sibaii, H., Bassyouni, I.H. et al. IL-17, IL-10, IL-6, and IFN-γ in Egyptian Behçet’s disease: correlation with clinical manifestations. Eur Cytokine Netw 30, 15–22 (2019). https://doi.org/10.1684/ecn.2019.0421

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ecn.2019.0421

Key words

Search

Navigation